LianBio income statement LIANY

Annual Quarterly

It recorded a net loss of $110.3 million. Diluted earnings per share were -$1.02.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2023
Sep 30, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Research and development
40
-29.8%
60
-62.3%
159
Selling, general and administrative
67
+8.8%
66
+77.9%
37
Operating income
-107
+9.8%
-125
+35.9%
-196
Pretax income
—
-111
+43.5%
-196
Income tax
1
+185.9%
-0
-164.3%
1
Net income
-88
+22.3%
-110
+43.8%
-196
Basic EPS
-0.82
-1.02
+82.1%
-5.71
Diluted EPS
-0.82
-1.02
+82.1%
-5.71
Weighted average shares, basic
107
108
+213.8%
34
Weighted average shares, diluted
107
108
+213.8%
34
Other measures
Depreciation and amortization
1
+38.9%
1
+91.6%
1
EBITDA
-105
+10.2%
-124
+36.2%
-195
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LIANY (OTC)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Princeton, NJ
SEC filer status
, Emerging growth company
SEC CIK
1831283

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.